Entering text into the input field will update the search result below

9 Meters stock falls despite drug showing promise in short bowel syndrome trial

Jun. 30, 2022 8:02 AM ET9 Meters Biopharma, Inc. (NMTRQ) StockBy: Ravikash Bakolia, SA News Editor

Modern Medicine Research Laboratory: Diverse Team of Multi-Ethnic Young Scientists Passes Samples in Petri Dish. Advanced Lab with High-Tech Equipment, Microbiology Researchers Design, Develop Drugs

gorodenkoff/iStock via Getty Images

9 Meters Biopharma (NASDAQ:NMTR) said its medicine vurolenatide met the main goal of reducing 24-hour total stool output (TSO) volume in seven out of 11 patients with short bowel syndrome in a phase 2 trial.

Based on

Recommended For You

More Trending News

About NMTRQ Stock

SymbolLast Price% Chg
Market Cap
PE
Yield (TTM)
Rev Growth (YoY)
Prev. Close
Compare to Peers

Related Stocks

SymbolLast Price% Chg
NMTRQ--
9 Meters Biopharma, Inc.